12:00 AM
 | 
Jun 16, 2014
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 6/13 cls
Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) Baird Brian Skorney Upgrade Outperform (from neutral) 125% $6.47
UBS Andrew Peters Upgrade Buy (from neutral)
Skorney also raised his target to $12 from $4 after Merck & Co. Inc. (NYSE:MRK) announced it will acquire HCV company Idenix Pharmaceuticals Inc. (NASDAQ:IDIX) for $24.50 per share in cash, or about $3.9B (see Cover Story). Skorney said preliminary evidence suggested Merck wasn't the only bidder. He said Achillion would...

Read the full 633 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >